Mesoblast (FRA:LWB) Interest Expense : €0.00 Mil (TTM As of Jun. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Mesoblast Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Mesoblast's interest expense for the three months ended in Jun. 2024 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2024 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Mesoblast's Operating Income for the three months ended in Jun. 2024 was € 0.00 Mil. Mesoblast's Interest Expense for the three months ended in Jun. 2024 was € 0.00 Mil. GuruFocus does not calculate Mesoblast's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Mesoblast Interest Expense Historical Data

The historical data trend for Mesoblast's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Interest Expense Chart

Mesoblast Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Interest Expense

Get a 7-Day Free Trial

-13.07

-8.89

-16.35

-17.95

-19.19

Mesoblast Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Mesoblast Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Mesoblast (FRA:LWB) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Mesoblast's Interest Expense for the three months ended in Jun. 2024 was €0.00 Mil. Its Operating Income for the three months ended in Jun. 2024 was €0.00 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2024 was €95.16 Mil.

Mesoblast's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as

GuruFocus does not calculate Mesoblast's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Mesoblast Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (FRA:LWB) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

MEOBF:USA MESO:USA LWB:Germany MSB:Australia

Address

55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000

Website

https://www.mesoblast.com

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Mesoblast Headlines

No Headlines